Janux shareholders elect three Class III directors and ratify EY as auditor

Janux Therapeutics, Inc.

Class III directors elected: Vickie Capps, Jay Lichter, and Jake Simson, each with >41 million votes for.
Ernst & Young ratified as independent auditor for FY2024 with 49,801,743 votes for, 1,682 against.
51,850,667 shares outstanding as of record date April 29, 2024; broker non-votes reported for director election.
All proposals passed; no other business items were voted on at the 2024 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.